rivaroxaban / Generic mfg. - LARVOL DELTA

Effectiveness and safety of rivaroxaban vs apixaban in patients with Atrial Fibrillation and Peripheral Artery Disease (ESC-WCC 2025) - No abstract available

Clinical • Atrial Fibrillation • Cardiovascular • Peripheral Arterial Disease

Impact of anemia on clinical outcomes of active cancer patients with low-risk pulmonary embolism receiving rivaroxaban: insight from the ONCO PE trial (ESC-WCC 2025) - No abstract available

Clinical • Clinical data • Cardiovascular • Pulmonary Embolism

Comparative effectiveness of dabigatran, rivaroxaban, and edoxaban on cardiac and renal outcomes in Asian patients with atrial fibrillation: a propensity score-weighted analysis (ESC-WCC 2025) - No abstract available

Clinical • HEOR • Atrial Fibrillation • Cardiovascular

Association between rivaroxaban and the prognosis of patients with acute myocardial infarction and new-onset atrial fibrillation (ESC-WCC 2025) - No abstract available

Clinical • Atrial Fibrillation • Cardiovascular • Myocardial Infarction

Abelacimab Has Fewer Bleeds Than Rivaroxaban, But Study Has Several Important Biases. (PubMed, Am Fam Physician) - No abstract available

Journal

Impact of NSAID Use on Bleeding Rates for Patients Taking Rivaroxaban or Apixaban. (PubMed, Fed Pract) - "However, this research was primarily conducted in mixed populations prescribed both direct oral anticoagulants (DOACs) and warfarin. A population health management tool may provide a safe approach for coprescribing NSAIDs with DOACs. Additional prospective studies are needed to quantify the comparative bleeding risk with concomitant NSAID use among DOACs alone."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

TELEHAEMATOLOGY FOR PATIENTS IN CONFLICT ZONE 1 YEAR EXPERIENCE (EHA 2025) - "Despite numerous constraints and operational challenges, the combination of telehealth and in-person interactions, allowed patients to access healthcare providers around the globe and provision of specialist medications not otherwise easily accesible."

Clinical • Anemia • Chronic Myeloid Leukemia • Follicular Lymphoma • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hemophilia • Immunology • Leukemia • Lymphoma • Myelofibrosis • Oncology • Polycythemia Vera • Rare Diseases • Sickle Cell Disease • MTHFR

RIVAROXABAN FOR THE PREVENTION OF THROMBOEMBOLISM IN IMID-CONTAINING MYELOMA TREATMENT REGIMENS (EHA 2025) - "Background: The immunomodulatory drugs (IMiDS) thalidomide, lenalidomide & pomalidomide are often used for treatment of multiple myeloma...Aspirin or prophylactic dose low molecular weight heparins (LMWH) were initially recommended for this purpose, however thrombosis rates remained elevated and LMWH requires parenteral administration.More recently direct oral anticoagulants (DOACS) have been used due to the advantage of oral administration. Aims: Several observational studies have described the use of apixaban in this setting...All patients were receiving 1st line treatment and the most common treatment regimens were daratumumab, bortezomib, thalidomide and dexamethasone (D-VTD), followed by daratumumab, lenalidomide and dexamethasone (DRD)... Rivaroxaban can be used for thromboembolism prophylaxis in patients with myeloma who are receiving IMiDS. Rates of thrombosis and bleeding are low and acceptable."

Cardiovascular • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Venous Thromboembolism

AMBULATORY THROMBOPROPHYLAXIS AND INCIDENCE OF THROMBOSIS IN PATIENTS WITH MULTIPLE MYELOMA: A SECONDARY CARE CENTRE EXPERIENCE (EHA 2025) - "One patient suffered a stroke whilst on Daratumumab-Velcade-Dexamethasone SACT (Figure). The majority of TEEs occurred in symptomatic MM patients who were not on SACT, and consequently not on AT according to our protocols. In our experience therefore, rivaroxaban or apixaban at prophylactic doses appears to be adequate in reducing the risk of TEEs in those on IMiDs in our local patient cohort, with no increase in major bleeding complications. There remains a question regarding the population of patients who are at risk of TEEs despite not being on IMiDs, with validated cancer-associated thrombosis risk scores, such as the Khorana score, not appearing to correlate with the risks in this group."

Clinical • Atrial Fibrillation • Cardiovascular • Hematological Malignancies • Multiple Myeloma • Oncology • Smoldering Multiple Myeloma • Thrombosis

UNIVERSAL USE OF NOVEL ORAL ANTICOAGULANTS IN NEWLY DIAGNOSED OR RELAPSED REFRACTORY MYELOMA PATIENTS RECEIVING IMMUNOMODULATORY DRUGS AS PART OF THEIR THERAPY (EHA 2025) - "Newly diagnosed or relapsed/refractory myeloma patients, who were diagnosed after 2020 and received either lenalidomide (besides a maintenance dose of 10 mgs per day with no dexamethasone) or pomalidomide as monotherapy or as part of combination therapy were included in the study...19 patients received apixaban 2.5 mg twice daily, while the remaining 82 patients received rivaroxaban at doses ranging from 10 to 20 mg per day (58 10 mgs, 18 15 mgs and 6 20 mgs per day) with the dosage determined based on comorbidities and prior thromboembolic events... Here, we present data from 101 patients who received NOAC prophylaxis while on IMIDs. The safety profile appears favorable, with only one major GI bleeding event attributed to a GI plasmacytoma and two thromboembolic events over a prolonged follow-up period. Based on these findings, we believe that NOACs should be the standard prophylactic measure for preventing IMID-associated thromboembolism in multiple myeloma patients."

Clinical • Immunomodulating • Cardiovascular • Coronary Artery Disease • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Obesity • Oncology • Plasmacytoma

THE UTILITY OF URINE QUALITATIVE ASSESSMENT FOR DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE (EHA 2025) - "The prescribed DOACs were rivaroxaban (18%), dabigatran (23%), edoxaban (26%), and apixaban (33%). The qualitative analysis of direct oral anticoagulants (DOACs) demonstrated a remarkable 99% concordance with the corresponding quantitative measurements across various clinical monitoring scenarios. This level of agreement underscores the utility of a rapid qualitative assessment tool, the validation of which in emergency conditions would help to enhance medical decision-making in acute care indications."

Clinical • Atrial Fibrillation • Cardiovascular • Hepatology • Liver Failure • Nephrology • Oncology • Renal Disease • Venous Thromboembolism

IDENTIFICATION OF NEW MOLECULAR MECHANISMS OF ANTITHROMBIN DEFICIENCY: RESULTS FROM A POLISH COHORT (EHA 2025) - "Thirteen probands (54.2%) received DOAC: six (25.1%) rivaroxaban (20 mg qd), five (20.8%) apixaban (2.5 mg or 5 mg bid) and two (8.3%) dabigatran (150 mg bid). Six probands were under anti-vitamin K treatments: four (16.7%) warfarin (8 or 10 mg qd) and two (8.3%) acenocoumarol (4 mg qd). Finally, four (16.7%) patients received antiplatelet therapy with acetylsalicylic acid (75 mg qd) and one (4.1%) received enoxaparin (150 mg/kg body weight qd).NGS detected SERPINC1 variants in 25 cases (86.2%): 12 missense (48%), 1 new (c.457T>C); 6 small deletions/insertions (24%), 2 new (c.962insG; c.402_403delGA+c.406_408+delGAGG), 5 intronic (20%) and 2 nonsense (8%)... Our study highlights the wide genetic heterogeneity involved in AT deficiency. We identified new genetic defects in SERPINC1, including intronic variants and confirmed the role of retrotransposon insertions as a new under-recognized mechanism contributing to congenital AT deficiency through in the genetic..."

Cardiovascular • Hematological Disorders • Respiratory Diseases • Venous Thromboembolism

Pharmacists' Knowledge of Abnormal Uterine Bleeding in Women on Anticoagulant Therapy: A French Survey. (PubMed, Clin Appl Thromb Hemost) - "These pharmacists reported a majority of cases in women of reproductive age, the drug the most frequently cited was rivaroxaban...Additionally, 99 (86.1%) pharmacists considered that they did not have enough skills to adequately advise female patients about abnormal uterine/genital bleeding under anticoagulant therapy.ConclusionOur study showed that community pharmacists are not the primary healthcare contact for patients with AUB under anticoagulant therapy. Despite this, the low frequency of pharmacist-patient interactions regarding AUB suggests potential under-diagnosis and under-communication of adverse effects that negatively impact the quality of life of women on anticoagulants."

Journal • Women's Health

Venous thromboembolism in patients with chronic kidney disease on dialysis: A Korean population-based nationwide study (2019–2022) (ISTH 2025) - "Conclusion(s) In Group A, the bleeding rates among patients treated with apixaban, and rivaroxaban were similar to to those observed in patients treated with warfarin. In Group A, major bleeding reached the plateau after 6 months of anticoagulation, while any gastrointestinal bleeding rates continued to rise gradually over the 12 months following initial anticoagulation. Table or Figure Upload"

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Gastroenterology • Hematological Disorders • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Venous Thromboembolism

Utility of PT and Anti-Xa to complement anticoagulation screening in Lupus Anticoagulation testing (ISTH 2025) - "Significant differences were observed in Anti-Xa and PT patterns in patients prescribed warfarin, DOACs, heparin, and those without anticoagulation...Results Out of the 80 total LAC orders (Table 1), 18 patients were anticoagulated with factor Xa DOACs (rivaroxaban or apixaban), with PT and Anti-Xa levels ranging from 10.6-26.6 s (median: 13.4 s) and 0.01-3.45 IU/mL (median: 0.55 IU/mL) respectively...One of the 8 referral specimens (no clinical or medication info provided) had an Anti-Xa of 1.87 IU/mL and PT of 16.4 seconds. Table or Figure Upload"

Immunology • Inflammatory Arthritis • Lupus

Direct oral anticoagulants in 67 patients with venous thromboembolism and severe thrombophilia. (ISTH 2025) - "All patients received long-term anticoagulation: 21 patients switched from warfarin to DOAC, and 46 patients were treated with DOACs, as first line therapy.Thirty-nine patients received long-term rivaroxaban (of them, 28 patients with 20 mg daily, 4 patients with reduced 10 mg daily dose, 7 patients treated with 20 mg for 1 year and then long term 10 mg), 10 patients received edoxaban (of them 1 patient treated with 30 mg, and 9 patients with 60 mg daily), and 18 patients received apixaban (of them 9 patents treated with 5 x 2 mg daily , 5 with reduced dose: 2.5 mg twice daily, and 4 with 5 x 2 daily for 1 year and then 2.5 x 2 for long term).One patient presented VTE during treatment with 20 mg rivaroxaban for atrial fibrillation and was then switched to full dose apixaban. We observed 2 cases of minor bleeding (both with 20 mg rivaroxaban): one patient suffered by microhematuria and gingival bleeding, and one patient presented occult blood in the stool with sigmoid..."

Clinical • Atrial Fibrillation • Cardiovascular • Infectious Disease • Metabolic Disorders • Oncology • Respiratory Diseases • Venous Thromboembolism

Artificial Intelligence Augmented Decision-Making approach for anticoagulant management (ISTH 2025) - "Among them, 4 patients were on warfarin, 10 patients were on rivaroxaban, and 28 patients took edoxaban. Two patients reported limb pain or swelling on anticoagulants. Table or Figure Upload"

Cardiovascular • Hematological Disorders • Musculoskeletal Pain • Pain • Respiratory Diseases • Venous Thromboembolism

Thrombin generation assay for the management of anticoagulant therapy in antithrombin deficiency (ISTH 2025) - "ETP median (range) values [nM.min] for individual anticoagulant groups: warfarin -TM=596 [396 – 642], +TM= 324 [466-322], rivaroxaban -TM=1768 [786-3685], +TM=583 [147-1923], apixaban -TM=1664 [1529-2106], +TM=742 [555-1603], dabigatran -TM=3417 [2794-4040], +TM=2639 [1966-3311] (Figure 1). Table or Figure Upload"

Cardiovascular • Venous Thromboembolism

Investigating the effects of anticoagulants on a FVIIa-Antithrombin complex assay (ISTH 2025) - "Methods Different dilutions of the anticoagulants – dabigatran, edoxaban, rivaroxaban, apixaban and unfractionated heparin (INHIBIREF X9222-K, Haematex) were used to spike normal plasma samples (Cryocheck™ normal plasma, Precision Biologics). Warfarinised samples demonstrated reduced level of FVIIa:AT complex by FVIIa-AT assay with slightly reduced FVIIIa:AT complex in the presence of all the other anticoagulants (Table 1). Table or Figure Upload"

Hematological Disorders

TFPIa activity suppression by Andexanet alfa is partially restored by protein S and factor V-short (ISTH 2025) - "Results AA efficiently reversed rivaroxaban in plasma. Similarly, AA-bound TFPIα was unable to inhibit FIXa generation in the absence of cofactors. However, when PS and FV-short were added, AA-TFPIα inhibited FIXa generation with 58% and 86% inhibition observed at 0.25nM and 1nM AA-TFPIα, respectively, compared to 95% inhibition by FXa-bound TFPIα."

PROS1

VMX-C001 bypasses the effects of FXa-direct oral anticoagulants in healthy adults: ROTEM analysis (ISTH 2025) - "Additionally, older adults (50–79 years) received FXa-DOACs (rivaroxaban, apixaban, edoxaban) for 3.5 days, followed by a single VMX-C001 dose (89–226 mg) or placebo (days 1–4). Results were consistent across groups and VMX-C001 doses. Table or Figure Upload"

Clinical

Safety/efficacy of pharmacologic prophylaxis in hospitalized adolescents with sickle cell disease (ISTH 2025) - "Rivaroxaban was the most prescribed anticoagulant: 66.3% (521/788)...Surgical splenectomy was significantly associated with VTE among the encounters with the diagnosis of VTE (53.3%; n=16/30) versus those without VTE (23.3%; n=177/761) [Odds ratio=4.23 (95% CI: 1.36-13.15) p=0.0128]. Table or Figure Upload"

Clinical • Cardiovascular • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • Venous Thromboembolism

Rivaroxaban levels monitorization in children: effect of age and weight on DOAC level (ISTH 2025) - "Outcome was not associated with dose modifications or rivaroxaban peak levels. Table or Figure Upload"

Clinical • Cardiovascular • Obesity • Pediatrics • Venous Thromboembolism

Pediatric cavernous sinus thrombosis with severe internal carotid stenosis: case report (ISTH 2025) - "Patient was treated with metronidazole and ceftriaxone for 28 days. She was started on unfractionated heparin (UFH) for 5 days then transitioned to Rivaroxaban therapy for 6 months. Repeat MRI/MRA/MRV at 6 months showed recanalization of the left CST without residual thrombosis of L CS and IJ vein and no stenosis/obstruction of the L ICA."

Case report • Clinical • Cardiovascular • Hematological Disorders • Musculoskeletal Pain • Otorhinolaryngology • Pain • Pediatrics • Thrombosis

Single centre review of aetiology and treatment of non-MPN related portal vein thrombosis (ISTH 2025) - "Long term anticoagulation strategies were, no anticoagulation 5%, LMWH therapeutic dose 2%, apixaban 5mg BD 28%, rivaroxaban 20mg OD 10%, warfarin standard-intensity (INR 2-3) 42%, warfarin higher-intensity (INR 2.5-3.5) 13%. Table or Figure Upload"

Clinical • Review • Cardiovascular • Fibrosis • Hepatology • Immunology • Infectious Disease • Myeloproliferative Neoplasm • Oncology • Thrombosis